Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Keywords: COPD, NVA237, QAB149, glycopyrronium bromide
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 511
Healthy volunteers: no

Brief summary:
The purpose of the study is to provide long term safety data of NVA237. This study will assess the safety and tolerability of a single dose strength of NVA237.

Detailed description:

Arms:
arm 1: NVA237 dose 1 arm 2: QAB149

Interventions: intervention 1: NVA237 intervention 2: Long-acting beta 2-agonist (LABA) intervention 3: Placebo
Intervention descriptions: intervention 1: NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI intervention 2: QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI intervention 3: Placebo to match QAB149

Protocol document: